Canadian Cancer Trials Group Bulletins

Trial Management Group


Closed to Accrual: CCTG IND.226

The CCTG IND.226 study has been closed to accrual.

A phase Ib study of durvalumab (MEDI4736) with or without tremelimumab in patients with advanced incurable solid malignancies with or without standard chemotherapy regimens, is closed after completion of target accrual.

Although the trial is closed accrual, treatment and follow up of patients will continue according to the protocol.

Thank you to everyone who has contributed to this study!

If you have any questions please contact the study coordinator Pamela Brown-Walker pbrown-walker@ctg.queensu.ca